In 2020, 1.4 million men were newly diagnosed with prostate cancer. Northern and Western Europe, the Caribbean, Australia/ New Zealand, North and South America, and Southern Africa have the highest age-standardized incidence rates [1]. This is why new, innovative approaches are required, which could treat prostate cancer more efficiently and with fewer adverse effects.
Immunotherapy for prostate cancer is one of the advancements in the treatment of the disease that has reported impressive outcomes in different stages of prostate cancer. Although traditionally believed to be useful in advanced prostate cancer only, recent clinical evidence shows that it can be used for early-stage prostate cancer, in some cases even as an alternative treatment option. Immunotherapy for prostate cancer is also effective in cases where other treatments are not effective and are no longer capable of preventing the development of prostate tumors. There are various forms of immunotherapy for prostate cancer in modern treatment regimens, and the German medical oncologists will determine which is the most appropriate for a specific patient.
Types of Immunotherapy for Prostate Cancer
Doctors in clinics in Germany use four types of immunotherapy for prostate cancer, each with unique advantages, mechanisms, and influence on the immune system:
- Dendritic cell vaccination is the most studied and widely applied for metastatic prostate cancer. The discovery of dendritic cells revolutionized cancer treatment and opened new possibilities in strengthening the immune response – an achievement that earned Ralph Steinman the 2011 Nobel Prize in Medicine. A cancer vaccine, based on pre-trained dendritic cells that recognize and attack prostate cancer cells, became the first FDA-approved therapy. Another promising cancer vaccine, LANEX, has shown encouraging results in clinical practice. Treatment costs €20,000 – €38,000, depending on the combination with other treatment options
- Monoclonal antibodies (bispecific T-cell engager, BiTE). BiTEs are engineered antibodies that bind both T-cells and prostate tumor cells, redirecting immune cells to kill cancer cells without requiring native receptors for tumor antigens. Drugs from this group already have FDA approval for other diseases, and applying them for treating prostate cancer is the next step in clinical research. One key advantage is that such therapy does not require individual synthesis for each patient, reducing the average cost of immunotherapy for prostate cancer. Treatment costs €375,000 – €420,000, with the final amount depending on therapy combinations and duration
- Immune checkpoint inhibitors (CTLA-4, PD-1/PD-L1). These are drugs that prevent tumor masking that would normally occur, allowing the immune system of human body to attack the cancerous cells. They can be used especially in prostate cancer patients with certain genetic mutations, including the mismatch repair deficiency (dMMR) or the high tumor mutation burden (TMB-H). Their usage enables application at virtually any level一from the early stages of prostate cancer to advanced disease, recurrence, or even in the instances of metastasis
- CAR T-cell therapy involves genetic modification of a patient’s white blood cells. Extracted leukocytes are engineered to recognize prostate tumors and actively target and eliminate cancer cells. Although highly promising in metastatic disease, this therapy is limited due to high costs and restricted access to gene technologies. Treatment costs €450,000 – €550,000, calculated individually depending on program length and therapeutic approach
When Is Immunotherapy Recommended for Prostate Cancer?
Contemporary immunotherapy strategies have become an effective therapy against prostate cancer and have proven to be incredibly efficient in both early-stage prostate cancer and advanced prostate cancer. They may be incorporated into a combined regimen together with surgery, chemotherapy, radiation therapy, and hormone therapy, which gives them more opportunities to treat prostate cancer.
The growing list of immunotherapy for prostate cancer candidates currently includes not only prostate cancer patients at the early stages but also men with metastatic prostate cancer who have had prostate removal but cannot get rid of the prostate cancer cells [2]. There are dendritic cell-based cancer vaccines that have recorded good results upon early introduction, and this can reduce the need for aggressive therapies. In cases, when postoperative radiation therapy and chemotherapy are ineffective, and the disease develops resistance to hormones, German medical oncologists turn to immunotherapy drugs.
The current immunotherapy regimens are designed to extend the life of patients with a metastatic disease, to limit tumor cell dissemination, and occasionally to reach a permanent remission, particularly in the earliest stages. Its effectiveness is confirmed by numerous studies and clinical practice. There are schedules of treatments一some types of treatments need frequent visits to the hospital, but new ones can be administered more conveniently. As an example, dendritic cell cancer vaccines can be administered in a single session, whereas some checkpoint-based drugs can be administered at home.
Immunotherapy prostate cancer is also required when patients cannot undergo surgery due to contraindication or when other methods of treatment are ineffective, such as recurrence and metastatic disease with resistant prostate tumor cells.
Recent studies have proved that immunotherapy not only helps in prostate cancer that has advanced but also in early stages. When used at the right time, it will slow the growth of the tumor, control symptoms, and prolong relapse-free survival. With increased tolerability, new approaches have become the first-line options for most prostate cancer patients. They are also undergoing clinical trials in combination with immune checkpoint inhibitors, and this represents a new frontier in the treatment of prostate cancer in all stages.
How Is Immunotherapy for Prostate Cancer Carried Out?
Monoclonal antibody therapy and immune checkpoint inhibitor therapy need initial laboratory testing. Genetic mutations that render the prostate cancer cells susceptible to this form of effective treatment are sought by doctors. Doctors also check kidney and liver functioning, the dimensions of the initial tumor in the prostate gland (unless surgery has been conducted), and the existence of metastases, which are located far away [3]. The drugs are mostly administered intravenously after three or four weeks.
The CAR T-cell treatment is performed in multiple steps. The first step is a thorough examination of the patient and blood tests with the isolation of leukocytes, which are then genetically altered. It normally takes two or three weeks to make a personalized drug. The procedure is carried out usually in a day hospital. Also, physicians can inject medications to dampen the immunosuppressive enviroment of the prostate tumors, enabling modified immune cells to more effectively destroy cancer cells.
Vaccination using dendritic cells is based on a two-step program. The initial visit involves clinical examination and laboratory examination in order to prepare the personalized LANEX-DC cancer vaccine. To develop it, specialists can rely on liquid biopsy or tumor tissue fragments. At the second visit, the patient is given the dendritic cell cancer vaccine, in addition to necessary symptomatic treatment. The two stages are performed on an outpatient basis, usually in a single day. This novel approach has demonstrated good outcomes following one injection and can be safely used alongside infusion-based immunotherapy. Clinical observations confirm that this strategy is not only useful in increasing life expectancy but also in enhancing the immune response against the prostate tumor cells.
In order to grasp the details of this potential treatment, we have interviewed Professor Frank Gansauge, a well-known medical oncologist and expert in the field of dendritic cell-based treatment of prostate cancer, with more than 22 years of experience in this field. His clinic has already recorded impressive breakthroughs in cancer treatment with new immunotherapeutic methods.
Prof. Frank Gansauge on 22 Years of Cancer Treatment Success: From Nobel Discovery to Modern Immunotherapy
Benefits of Immunotherapy for Prostate Cancer
Designed to treat advanced prostate cancer, immunotherapy has since become effective in virtually all stagesーfrom early-stage prostate cancer to metastatic castration resistant prostate disease. This treatment has become a real breakthrough in the current cancer therapy.
Immunotherapy for prostate cancer has the following advantages:
- Effective in work irrespective of the sensitivity of prostate tumor cells to hormones
- Treats initial lesions in the prostate gland and metastasis
- Removes the disease even in cases where the normal chemotherapy is unable to kill cancer cells
- Extends life span and quality of life
- Combinations with other treatment modalities like surgery, hormone therapy, or radiation have good results
- Immune checkpoint inhibitors and adoptive cell therapy are modern immunotherapy medications whose usage is usually well tolerated and seldom results in serious adverse events
With such advantages, immunotherapy for prostate cancer has emerged as one of the most promising and efficient treatment approaches for prostate cancer patients, particularly those with metastatic prostate cancer or resistant prostate cancer.
| Toxicity | Therapy Duration | Early Stage Effectiveness (5-year survival rate) | Duration of treatment effect | Treatment Cost | |
|---|---|---|---|---|---|
| Chemotherapy | High (65-80%) | Depending on the cancer stage, up to lifelong | up to 75%, with significant side effects | Short-term effect, limited to the course of treatment | €80,000 - €150,000 for the full course |
| Hormone therapy | Low (10-15%) | Given for several months, usually followed by chemotherapy | up to 70% for hormone-sensitive cases only | The effect is present only during treatment | €10,000 - €15,000 |
| Dendritic cell vaccines | Very low (about 1%) | Single injection and lifelong immunity | up to 95% with minimal impact on quality of life | Reliable long-term result, long-lasting remission | €20,000 - €38,000 |
| Targeted therapy | Low (15-20%) | Depending on the cancer stage, treatment may take about a year | up to 75% for matching mutations only | The effect is quite long-lasting in the presence of specific mutations in the tumor | €375,000 - €420,000 for the full course |
*Booking Health data. Success rates vary depending on cancer type, stage, and individual patient factors.
Combining Immunotherapy with Conventional Treatments
The incorporation of immunotherapy techniques in prostate cancer treatment and the use of conventional treatment methods have become standard in contemporary prostate cancer treatment. In Germany, physicians thoroughly examine the condition of each of their patients to determine the best combination of therapies to improve the immune response, attack prostate cancer cells more precisely, and lead to long-term control of the disease. This strategy enables patients with early prostate cancer, advanced prostate cancer, or metastatic prostate cancer to receive customized regimens that are effective and secure.
Immunotherapy and Surgery
Surgical intervention is still one of the main methods of treating early prostate cancer and is a part of the treatment of advanced disease. The use of surgical removal of the prostate gland, in combination with cancer vaccines or adoptive cell therapy, reinforces the immune system of the body against remnant prostate tumor cells. Immunotherapy prostate cancer before and after the operation can be used to destroy cancerous cells that might be left behind during surgery, hence lowering the chances of metastatic cancer [4]. The use of prostate-specific antigen provides medical oncologists with an opportunity to monitor recurrence and to make changes in the treatment options.
Radiation Therapy and Immunotherapy
Radiation therapy removes existing tumor cells in localized cancer. Immune checkpoint inhibitors and dendritic cell vaccines activate immune cells to identify and destroy prostate cancer cells that have left. This combination is especially helpful in cases of metastatic castration resistant prostate cancer, whereby traditional radiation treatment might be insufficient to contain tumor growth. In Germany, clinics focus on accurate dosing and timing to maximize the effectiveness of treatment, reduce toxicity, and enhance patient outcomes.
Immunotherapy and Hormone Therapy
Prostate cancer cells can be suppressed by hormone therapy, but when prostate cancer becomes advanced, it can become resistant to this treatment. Immune checkpoint inhibitors or adoptive cell therapy introduced at this point reinitiate the immune system to attack hormone-insensitive prostate tumor cells. It is clinically observed that when these modalities are combined, they are more effective in killing cancer cells and lowering the chances of disease progression.
Immunotherapy and Chemotherapy
In advanced disease and in cases of metastatic prostate cancer, chemotherapy is still a standard method, although it undermines the immune system of the body. Cancer vaccines or CAR T-cell therapy are beneficial in ensuring an active immune response that can attack prostate cancer cells. This synergistic method enables medical oncologists to optimize treatment options while managing the growth of the tumor and enhancing the quality of life of prostate cancer patients.
Personalization and Monitoring
The need to combine immunotherapy for prostate cancer with conventional treatments must be closely monitored. Imaging, molecular tests, and prostate-specific antigen levels provide medical oncologists with guidance on how to modify therapy. Individualized plans can be used in order to make sure that the immune checkpoint inhibitors, adoptive cell therapy, or other immunotherapy drugs can be applied to supplement surgery, radiation, and chemotherapy without compromising patient safety. This strategy is not only very effective in attacking prostate cancer cells, but it also offers a guideline in the treatment of prostate cancer at all stages, including early-stage prostate cancer and metastatic castration resistant prostate disease.
Future Perspectives
New areas of research continue to examine new approaches to cancer vaccines, checkpoint inhibitors, and adoptive cell therapy combined with advanced therapies. Through these strategies, there is a chance to boost the competence of the immune cells to kill cancerous cells, regulate the growth of tumors, and boost the survival rates in general [5]. The emphasis on high-quality clinical procedures in Germany guarantees that patients will be able to receive effective treatment一this has made it a top-choice destination for prostate cancer treatment.
Why Germany Stands Out for Prostate Cancer Treatment
Germany is known globally for having high-quality prostate cancer treatment and advanced oncology care. In Germany, medical facilities have the latest diagnostic equipment, such as molecular profiling, prostate-specific antigen test, and high-end imaging, which enables accurate treatment of prostate cancer.
The main benefits of the treatment of prostate cancer in Germany include:
- Access to new treatment options: Patients can now access new forms of immunotherapy for treating prostate cancer, such as cancer vaccines, CAR T-cell therapy, and adoptive cell therapy.
- Individualized treatment programs: German medical oncologists create individual plans and select the most effective treatment methods based on the stage of the disease, the patient's genetic features, and state of health.
- Cobmination: Immunotherapy can be combined with surgery, radiation, hormone therapy, or chemotherapy in order to enhance the treatment effect and maximize the survival in metastatic prostate cancer or advanced disease.
- Safety and high level of oversight: The immune response and potential side effects are detected constantly, which ensures that patients can tolerate treatment.
- Comprehensive patient care: Germany focuses on the patient-centered approach and improving quality of life, as well as patient education about the appropriate treatment for cancer cells.
A Medical Journey: Every Step of the Way With Booking Health
Finding the best treatment strategy for your clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly specialized innovative treatment options.
To make an informed choice and get a personalized cancer management plan, which will be tailored to your specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating complex management programs in each individual case. As a reputable company, Booking Health offers personalized treatment plans with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment. We provide:
- Assessment and analysis of medical reports
- Development of the medical care program
- Selection of a suitable treatment location
- Preparation of medical documents and forwarding to a suitable clinic
- Preparatory consultations with clinicians for the development of medical care programs
- Expert advice during the hospital stay
- Follow-up care after the patient returns to their native country after completing the medical care program
- Taking care of formalities as part of the preparation for the medical care program
- Coordination and organization of the patient's stay in a foreign country
- Assistance with visas and tickets
- A personal coordinator and interpreter with 24/7 support
- Transparent budgeting with no hidden costs
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner who assists you in pursuing stronger health and a better quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with innovative methods and with leading specialists in this field.
Modern Cancer Treatment: Patient Journeys with Booking Health
Frequently Asked Questions About Prostate Cancer Immunotherapy
Send request for treatmentProstate cancer immunotherapy involves drugs that induce the immune system of an individual to identify and destroy cancer cells. It is a treatment aimed at certain proteins or receptors of the cancer cells.
Immunotherapy is a specific form of treatment, and it has fewer side effects than the usual treatments, and it may lead to permanent remission. It offers a new hope to patients with advanced or resistant prostate cancer.
The effectiveness of the therapy is monitored through regular imaging tests, blood tests, and clinical evaluations. These tests assist physicians in assessing the effectiveness of the therapy and making any necessary modifications.
Examples of side effects are fatigue, skin reactions, and flu-like symptoms. Severe adverse effects are infrequent, yet may happen and have to be closely monitored during treatment.
Yes, immunotherapy may be applied in combination with standard therapies, such as chemotherapy, radiation treatments, and targeted therapies. A combination of treatments will increase the overall effect and will be more effective and beneficial to patients.
Germany has high technologies and oncologists with a high level of experience, as recognized by the German Cancer Society. A tumor board with multidisciplinary review is applied to every case.
There are different treatment costs一dendritic cell vaccines €20 000 - €38,000, monoclonal antibody treatment €375 000 - €420 000, and CAR T-cell therapy €450,000 - €550,000. The cost will largely depend on the program and a combination of therapies.
Research centers in Germany are currently conducting trials of combined immunotherapies and personalized vaccine therapy. Large institutions such as the National Center for Tumor Diseases and the German Cancer Research Center offer eligible patients the opportunity to participate in clinical trials of experimental treatments.
Toxicity of dendritic cell vaccines is about 1% – this is the safest option. Hormone therapy shows moderate toxicity of 10-15%, targeted therapy – 15-20% toxicity. Chemotherapy impacts quality of life the most.
Treatment duration varies considerably depending on the approach selected. Dendritic cell vaccines require only a single injection that creates lifelong immunity, representing the most convenient option. Hormone therapy is given for several months before transitioning to other treatments, while targeted therapy may continue for about a year depending on cancer stage. Chemotherapy duration extends up to lifelong administration in some cases.
With vaccines with dendritic cells, prostate cancer patients can achieve up to 95% 5-year survival. Chemo- and targeted therapy can offer up to 75%. Hormone therapy is quite effective, up to 70%, but it works only in hormone-sensitive cases.
Vaccination with dendritic cells provides long-term results – lifelong anticancer immunity is a reality after just a single injection. Hormone therapy and chemotherapy effects are significant only during active treatment. Targeted therapy demonstrates long-lasting effects, but its administration is limited to the presence of specific mutations.
In Germany, a patient pays €20,000-€38,000 for dendritic cell vaccines, €10,000-€15,000 for hormone therapy. Targeted therapy costs €375,000-€420,000 for the full course, and the chemotherapy full course is about €80,000-€150,000.
In Germany prostate cancer patients can access advanced immunotherapy programs. Treatments are individualized and administered in specialized centers. Also they are combined with standard oncology care to enhance immune response.
Germany has one of the most effective immunotherapies for prostate cancer一 dendritic cell vaccines, CAR T-cell therapy, as well as active immunotherapy vaccines. They are also available to patients in dedicated cancer facilities, where patients can get high-quality care and specific programs tailored to each stage of the disease.
Booking Health support with immunotherapy in Germany assists international patients with the organization of appointments, choosing the most successful clinics, and organizing transportation and treatment. The BH team takes patients through the process of medical paperwork, insurance, and follow-up after treatment, so they can access groundbreaking immunotherapy to treat prostate cancer in Germany.
Choose treatment abroad and you will for sure get the best results!
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Bohdan Mykhalniuk. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] Oskar Bergengren, Kelly R Pekala, Konstantina Matsoukas et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review. Eur Urol. 2023 May 16;84(2):191–206. doi: 10.1016/j.eururo.2023.04.021. [DOI] [PMC free article]
[2] Liam Dwyer, Claudia Leslie, Rhiannon Mellor et al. Immunotherapy in metastatic prostate cancer. Ther Adv Med Oncol. 2025 Jul 3;17:17588359251347857. doi: 10.1177/17588359251347857. [DOI] [PMC free article]
[3] Dhivya Sridaran, Elliot Bradshaw, Carl DeSelm et al. Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach. Cell Rep Med. 2023 Sep 21;4(10):101199. doi: 10.1016/j.xcrm.2023.101199. [DOI] [PMC free article]
[4] Jide He, Jialong Wu, Ziang Li et al. Immunotherapy Vaccines for Prostate Cancer Treatment. Cancer Med. 2024 Oct 28;13(20):e70294. doi: 10.1002/cam4.70294. [DOI] [PMC free article]
[5] Shivani Handa, Bandhul Hans, Shokhi Goel et al. Immunotherapy in prostate cancer: current state and future perspectives. Ther Adv Urol. 2020 Sep 3;12:1756287220951404. doi: 10.1177/1756287220951404. [DOI] [PMC free article]
Read:
Comprehensive Guide to Prostate Cancer Treatment: New and Standard Treatment Options
NanoKnife® prostate cancer treatment
Prostate cancer treatment with dendritic cells in Germany
Article menu:
- Types of Immunotherapy for Prostate Cancer
- When Is Immunotherapy Recommended for Prostate Cancer?
- How Is Immunotherapy for Prostate Cancer Carried Out?
- Benefits of Immunotherapy for Prostate Cancer
- Combining Immunotherapy with Conventional Treatments
- A Medical Journey: Every Step of the Way With Booking Health
- Frequently Asked Questions About Prostate Cancer Immunotherapy
Don't know where to start?
Contact Booking Health
